European Companies Search Engine

EU funding (€22.6M): BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL Hor 1 Sept 2022 EU Research and Innovation programme "Horizon"

Overview

Text

BUILDING A SUSTAINABLE EUROPEAN INNOVATION PLATFORM TO ENHANCE THE REPURPOSING OF MEDICINES FOR ALL

REMEDi4ALL aims to establish Europe's leadership globally in the repurposing of medicines by creating a vibrant community of practice covering all relevant sectors and disciplines. REMEDi4ALL will establish and operate a permanent European research and innovation platform comprising the complete value chain for cutting edge, patient-focused repurposing, collaborating with users to execute high potential projects at any phase of development, upskilling all stakeholder groups through a comprehensive education and training portfolio, and advancing cross-sectoral policy dialogue with all relevant stakeholders and thought leaders. The tools and processes developed assembled in REMEDi4ALL will be validated in a portfolio of 4 ambitious preclinical and clinical phase demonstrators, representing high patient need in a variety of disease areas, including oncology, rare and infectious diseases. The REMEDi4ALL platform will operate a complete, harmonised and accessible value chain integrating the scientific, methodological, financial, legal, regulatory, and intellectual property aspects of the repurposing approach in a goal-oriented and patient-centric approach. Working closely together with research funders and the patient community, REMEDi4ALL will engage and support a substantial user base and concomitant investments through a permanently sustainable entity, working closely with the permanent European Infrastructures and partners. The community of practice comprises leading academic and clinical facilities and infrastructures, medicines regulators, health technology assessors, public agencies and funders, small and large industry, state-of-the-art artificial intelligence and in silico tools, and a global network of collaborators for optimal knowledge exchange. REMEDi4ALL will substantially increase Europe's capacity to develop high quality repurposed medicines and implement them into the market, through its complete value chain and consensus-based policy development mission.


Funded Companies:

Company name Funding amount
Beacon: for Rare Diseases Ltd. ?
Antikankerfonds - Fonds Anticancer-Anticancer Fund €427,438
Bundesinstitut FUR Arzneimittel UND Medizinprodukte €101,875
Chemotargets SL €505,500
Dompe Farmaceutici S.p.A. €255,188
Eatris Eric €4,308,655
Ecrin European Clinical Research Infrastructure Network €966,500
Eurordis - Rare Diseases Europe €1,388,725
Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. €2,009,859
Fundacion para La Investigacion Biomedica del Hospital Universitario Ramon y Cajal €0.00
Helsingin Yliopisto €1,269,575
Istituto Di Ricerche Farmacologiche Mario Negri €787,769
Istituto Nazionale Tumori Fondazione Pascale €2,322,680
Istituto Ortopedico Rizzoli €631,725
Karolinska Institutet €1,684,325
Medicines for Europe €208,063
Servicio Madrileno de Salud €349,508
Syreon Kutato Intezet kft. €791,813
Teamit Institute SL €0.00
Teamit Research SL €1,818,463
Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts €656,674
Univerza V Ljubljani €502,000
Uppsala Universitet €885,638
Zorgonderzoek Nederland ZON €689,563

Source: https://cordis.europa.eu/project/id/101057442

The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: Beacon: for Rare Diseases Ltd., Cambridge.